GlassScriptPhysician profile
Surindar K Jolly
NPI 1164479911
$25,006.71
in general payments reported to CMS, 2019-2025
59 companies · $9,639 in 2025
The $9,639 reported for 2025 was more than what 92% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,334 · 2020: $1,852 · 2021: $2,606 · 2022: $2,592 · 2023: $2,139 · 2024: $2,845 · 2025: $9,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,594 · Consulting Fee: $5,610 · Travel and Lodging: $1,351 · Education: $68.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,593.90 |
| Consulting Fee | $5,610.00 |
| Travel and Lodging | $1,351.12 |
| Education | $68.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $7,053.14 | 2025 | |
| Ucb, INC. | $2,754.39 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Amneal Pharmaceuticals LLC | $2,116.64 | 2019-2025 | Rytary, Crexont |
| Biogen, INC. | $1,294.92 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Celgene Corporation | $1,163.19 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $737.62 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $722.72 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $655.24 | 2020-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $615.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $615.01 | 2019-2022 | |
| Eisai INC. | $595.33 | 2019-2025 | |
| Neurelis, INC. | $571.41 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $503.62 | 2020-2025 | Cobenfy, Zeposia |
| Argenx US, INC. | $402.53 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $323.63 | 2019-2023 | Aimovig |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surindar Jolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.